Fox Run Management L.L.C. Buys Shares of 18,748 Orthofix Medical Inc. (NASDAQ:OFIX)

Fox Run Management L.L.C. acquired a new stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 18,748 shares of the medical device company’s stock, valued at approximately $327,000.

Other institutional investors have also recently made changes to their positions in the company. HighVista Strategies LLC purchased a new stake in Orthofix Medical in the third quarter valued at about $1,689,000. JPMorgan Chase & Co. raised its position in shares of Orthofix Medical by 480.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company’s stock valued at $1,318,000 after purchasing an additional 69,848 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Orthofix Medical by 90.0% in the 4th quarter. Teacher Retirement System of Texas now owns 135,009 shares of the medical device company’s stock valued at $2,357,000 after purchasing an additional 63,939 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Orthofix Medical in the 4th quarter worth approximately $1,003,000. Finally, HighTower Advisors LLC grew its position in Orthofix Medical by 114.9% during the 3rd quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company’s stock worth $1,393,000 after purchasing an additional 47,680 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Wall Street Analyst Weigh In

OFIX has been the subject of several research reports. Roth Mkm reiterated a “buy” rating and set a $22.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th. Canaccord Genuity Group restated a “buy” rating and issued a $24.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. Finally, StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Orthofix Medical Trading Down 1.4 %

Shares of Orthofix Medical stock opened at $16.28 on Thursday. The stock has a market cap of $635.28 million, a PE ratio of -5.20 and a beta of 1.06. The firm has a fifty day moving average price of $17.71 and a 200 day moving average price of $17.37. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Insiders Place Their Bets

In other Orthofix Medical news, CEO Massimo Calafiore sold 9,203 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $17.14, for a total value of $157,739.42. Following the completion of the transaction, the chief executive officer now directly owns 124,151 shares of the company’s stock, valued at approximately $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Julie Andrews sold 4,655 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the sale, the chief financial officer now directly owns 28,312 shares in the company, valued at $506,501.68. The trade was a 14.12 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,999 shares of company stock valued at $512,497. Company insiders own 2.60% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.